The research article: "Acute Epithelial Toxicity Is Prognostic for Improved Prostate Cancer Response to Radiation Therapy: A Retrospective, Multicenter, Cohort Study" from Thomas Eade FRANZCR, Ananya Choudhury MA, PhD, MRCP, FRCR, Alan Pollack MD, PhD, Matthew Abramowitz MD, Felix M. Chinea MD, Linxin Guo BSc, MHSc, Jason Kennedy BSc, MSc, Sandra Louw, George Hruby FRANZCR, Andrew Kneebone FRANZCR, Catharine West PhD, has been published in the International Journal of Radiation Oncology Biology Physics, Volume 101, Issue 4, 15 July 2018, Pages 957-963.
Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-Effects and Improve Quality of Life in Cancer Survivors
The purpose of this international study is to try to predict which patients are more likely to have side effects from radiotherapy
Since March 2014 the REQUITE study has been registered with ISRCTN: https://doi.org/10.1186/ISRCTN98496463
ISRCTN supports transparency in clinical research, helps reduce selective reporting of results and ensures an unbiased and complete evidence base.
We are very pleased to show you the REQUITE Patient Leaflet! In this Leaflet we would like to inform you on the progress of this project and to thank all the patients who agreed to take part in the REQUITE study. The Leaflet is available in English, Spanish, French, German, Italian and Dutch.
- The first day of the Final REQUITE Symposium (17th July, 8:30-17:30, CityLabs) was open to REQUITE consortium me
ESMO is and continues to be a leading force of high-quality oncology education, a platform for immense international visibility for scientific research, and a proud contributor to continuous improvements in patient care.
For more information: website
ASTRO’S Annual Meeting is the premier radiation oncology scientific event in the world and draws more than 11,000 attendees each year.
Abstract Submission Site Opens: December 13, 2017
Abstract Submission Site Closes: February 14, 2018
The annual congress of ESTRO will take place 26-30 April 2019 in Milan, Italy. ESTRO 38 will offer all professionals of oncology the chance to share knowledge, practice and advances in the field, within the ever warm and dynamic environment of the ESTRO meetings. ‘Targeting optimal care, together’ will be the theme of ESTRO 38 and through these few, however impactful words, the Scientific and organising committees would like to put a spotlight on the multiprofessional and multidisciplinary aspect of our specialty. The theme also represents our strength: we are all working towards a common goal for improved patient outcomes, and this will be expressed throughout the scientific programme... See for more information the website